Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010;24(5):295-9.
doi: 10.1002/jcla.20404.

Serum KL-6 levels in lung cancer patients with or without interstitial lung disease

Kunihiko Miyazaki  1 , Koichi Kurishima, Katsunori Kagohashi, Mio Kawaguchi, Hiroichi Ishikawa, Hiroaki Satoh, Nobuyuki Hizawa
Affiliations
Comparative Study

Serum KL-6 levels in lung cancer patients with or without interstitial lung disease

Kunihiko Miyazaki et al. J Clin Lab Anal. 2010.

Abstract

Background: It is not known whether lung cancer patients with interstitial lung disease (ILD) might have higher serum levels of KL-6, a high molecular weight glycoprotein classified as a polymorphic epithelial mucin. In addition, prognosis of these patients with elevated serum KL-6 levels might be poorer than that with normal KL-6 levels, but it has not been well clarified.

Methods: Serum KL-6 levels in 273 lung cancer patients with or without ILD, and prognostic significance of elevated serum KL-6 levels in these patients were studied using uni- and multivariate analyses.

Results: Serum KL-6 levels were elevated (>500 U/ml) in 73.5% of lung cancer patients with ILD and in 33.7% of those without ILD. Serum KL-6 levels in lung cancer patients with ILD were significantly higher than those without ILD. In lung cancer patients with ILD, elevated serum KL-6 has no prognostic significance, but in those without ILD, however, it was one of the unfavorable prognostic factors.

Conclusions: Elevated serum KL-6 levels can be observed in lung cancer patients both with and without ILD. Having ILD has strong prognostic impact in patients with lung cancer. In those without ILD, however, elevated KL-6 levels may be related to poor prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival of lung cancer patients with ILD (bold line) and without ILD. There was statistical significant difference between them (P=0.001, Logrank test).
Figure 2
Figure 2
Serum KL‐6 levels in 68 lung cancer patients with ILD and those in 205 lung cancer patients without ILD.
Figure 3
Figure 3
Survival of lung cancer patients with ILD who had elevated serum KL‐6 levels (bold line) and normal KL‐6 levels.
Figure 4
Figure 4
Survival of lung cancer patients without ILD who had elevated serum KL‐6 levels (bold line) and normal KL‐6 levels. There was statistical significant difference between them (P=0.001, Logrank test).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mizushima Y, Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest 1995;108:1272–1277. - PubMed
    1. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc 2002;77:763–770. - PubMed
    1. Ohyabu N, Hinou H, Matsushita T, et al. An essential epitope of anti‐MUC1 monoclonal antibody KL‐6 revealed by focused glycopeptide library. J Am Chem Soc 2009;131:17102–17109. - PubMed
    1. Oyama T, Kohno N, Yokoyama A, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL‐6, a human MUC1 mucin. Lung 1997;175:379–385. - PubMed
    1. Takahashi T, Munakata M, Suzuki I, Kawakami Y. Serum and bronchoalveolar fluid KL‐6 levels in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 1998;158:1294–1298. - PubMed

Publication types

MeSH terms